Zoetis Inc (ZTS)
Sous-évaluéFondamental
72
Prix
$69.94
Capitalisation boursière
$29.52B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$9.53B
12 derniers mois (au 30/06/2026)
Résultat net
$2.64B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$2.28B
Capitaux propres totaux
$3.42B
Passif total
$12.07B
Ratio de liquidité général
3.08
Couverture des intérêts
-
Dette/EBITDA
2.27
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$112.17
Prix actuel
$69.94
Marge de sécurité
+37.7%
Fourchette de juste valeur
$72.91 - $151.42
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
11.41
ROE
78.3%
Ratio P/B
9.17
P/FCF
12.46
Marge brute
71.7%
ROIC
-
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
-
WACC
6.8%
ROIC − WACC
-
Critères d'analyse fondamentale
Réussi (18)
- EPS shows upward trend
- EPS CAGR 19.62%
- Gross Margin 71.7%
- P/FCF 12.46
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 69.3%
- Revenue Growth 5Y 7.2%
- Analyst Consensus 50% Buy
- PEG Ratio 0.93
- Earnings Quality (OCF/NI) 1.08
- Share Dilution -2.3%
- Net Margin Trend 27.7% vs 27.6%
- Piotroski F-Score 6/9
Échoué (6)
- Price CAGR 3.15%
- P/B Ratio 9.17
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.5%
Indisponible (4)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Ms. Kristin C. Peck | CEO & Director | 54 |
| Ms. Roxanne Lagano | Executive VP, General Counsel & Corporate Secretary | 60 |
| Mr. Wetteny N. Joseph CPA | Special Advisor to the CEO | 53 |
| Dr. Robert J. Polzer Ph.D. | Scientific Advisor | 56 |
| Mr. Jamie Brannan | Executive VP & Chief Commercial Officer | 52 |
| Mr. James K. Saccaro | Executive VP, CFO & COO | 52 |
| Mr. Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | 46 |
| Mr. Steven Frank | Vice President of Investor Relations | - |
| Ms. Julie A. Fuller | Executive VP, Chief Human Resources Officer & Global Operations | 52 |
| Mr. Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations | 37 |
Risque d'audit
5
Risque du conseil
2
Risque de rémunération
6
Risque droits des actionnaires
7
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-12
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-06
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-06
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for ZTS, sourced from Markets Gazette.
- 5/10/2026NEGATIVEZoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?
Zoetis Inc. was among the top large-cap decliners last week, experiencing a significant sell-off. This downturn was primarily attributed to weak earnings reports, cautious forward guidance from the company, and subsequent reductions in analyst price targets. The broader market sentiment also played a role, with declines seen across healthcare, software, networking, and industrial sectors. Investors are advised to monitor Zoetis's upcoming earnings calls and management commentary for signs of a potential turnaround or further headwinds.
via Markets Gazette